Many cytokines and growth factors induce transcription of immediate early response genes by activating members of the Signal Transducers and Activators of Transcription (STAT) family. Although signi®cant progress has been made in understanding the events that lead to the activation of STAT proteins, less is known about the regulation of their expression. Here we report that murine embryonic ®broblasts derived from c-Cbl-de®cient mice display signi®cantly increased levels of STAT1 and STAT5 protein. In contrast, STAT2 and STAT3 expression, as well as the levels of the tyrosine kinases Jak1 and Tyk2, appear to be regulated independently of c-Cbl. Interestingly, the half-life of STAT1 was unaected by the presence of c-Cbl, indicating that c-Cbl acts independently of STAT1 degradation. Further analysis revealed similar levels of STAT1 mRNA, however, a dramatically increased rate of STAT1 protein synthesis was observed in c-Cblde®cient cells. Thus, our ®ndings demonstrate an additional control mechanism over STAT1 function, and also provide a novel biological eect of the Cbl protein family. Oncogene (2001) 20, 7326 ± 7333.
Introduction
Signal transducers and activators of transcription (STATs) represent a family of transcription factors that mediate cytokine and growth factor-induced activation of immediate early response genes in the absence of de-novo protein synthesis Larner et al., 1993) . Seven genetically distinct mammalian STAT proteins have been described (Fu, 1992; Lin et al., 1996; Liu et al., 1995; Quelle et al., 1995; Yamamoto et al., 1994; Zhong et al., 1994a,b) , and related signaling molecules have been found in Drosophila (Hou et al., 1996; Yan et al., 1996) and Dictyostelium (Kawata et al., 1997) . All STAT proteins are activated through rapid tyrosine phosphorylation (Gupta et al., 1996; Heim et al., 1995) , which is required for dimerization (Shuai et al., 1994) , nuclear translocation (Mowen and David, 1998) and DNA binding Fu, 1992) . Tyrosine phosphorylation of STAT proteins in response to cytokines requires the activity of one or more Janus tyrosine kinases (JAKs), whereas STAT phosphorylation via growth factor receptors such as the epidermal growth factor receptor depends on the intrinsic kinase activity of the receptor. In addition to phosphorylation of STAT1 and STAT3 on Tyr701 or Tyr705, respectively, further phosphorylation on Ser727 is essential to maximize their transactivation capabilities (Wen et al., 1995) . Although more emphasis had been placed on STAT activation than on inactivation, several negative regulatory components of the Jak/ STAT pathway have recently been identi®ed. These proteins target either the activating Jak kinase, or aect the phosphorylated STAT protein directly. However, in either case, it is the activation state or the functionality of the STAT proteins that is aected rather than their protein levels.
The proto-oncogene c-Cbl was originally identi®ed as the mammalian ortholog of the v-Cbl oncogene isolated from the Cas NS-1 murine leukemia virus (Blake et al., 1991; Langdon et al., 1989) . Homologs of c-Cbl have been found in Drosophila (D-Cbl) (Meisner et al., 1997) and in C. elegans (sli-1) (Yoon et al., 1995) . The 120 kDa cytoplasmic gene product of c-Cbl, which lacks any detectable enzymatic activity, contains in its amino-terminus a unique SH2-domain, an EF hand domain, and a highly basic region. The COOHterminal half contains a proline-rich domain, several tyrosine phosphorylation sites, and a ubiquitin-associated (UBA) domain. A centrally located ring-®nger domain has been demonstrated to be essential for cCbl's function as a ubiquitination-promoting or E3 factor (Joazeiro et al., 1999) . Two oncogenic forms of c-Cbl lack this critical feature. The v-Cbl protein represents a carboxy-terminal deletion, lacking the ring-®nger and the proline-rich domain. 70Z-Cbl, which was isolated from a pre-B cell line, contains an internal deletion within the ring-®nger domain (amino acids 366 ± 382), illustrating that mutations or deletions of the ring ®nger domain can be responsible for the oncogenic potential of c-Cbl (Blake et al., 1991) .
Much of the eort in understanding the function of c-Cbl has been focused on its role in the ubiquitin-dependent degradation of growth factor receptors such as the epidermal growth factor receptor or the CSF-1 receptor (Lee et al., 1999; Levkowitz et al., 1998 Levkowitz et al., , 1999 Wang et al., 1999; Waterman et al., 1999) . In these cases, c-Cbl facilitates the multi-ubiquitination of activated, tyrosine phosphorylated receptor tyrosine kinases, thereby downregulating an activated signal transduction pathway. Similarly, c-Cbl negatively regulates antigen receptor-mediated signaling events by decreasing the levels of activated, tyrosine phosphorylated ZAP70 or Syk (Andoniou et al., 2000; Ota and Samelson, 1997; Thien et al., 1999) . Consistent with these biochemical ®ndings, c-Cbl-de®cient mice display lymphoid hyperplasia and increased antigen receptor signaling (Murphy et al., 1998; Naramura et al., 1998) .
c-Cbl was found to be tyrosine phosphorylated in response to interferons (Uddin et al., 1996) and interleukins (Odai et al., 1995) , however, the role of c-Cbl in the Jak/STAT signaling cascade remains largely unexplored. Here we show that c-Cbl exerts a negative regulatory function on interferon signaling by controlling STAT1 proteins levels. Intriguingly, c-Cbl decreased STAT1 levels in a ligand-independent manner, and acted by suppressing protein synthesis rather than by promoting protein degradation.
Results
c-Cbl7/7 cells display increased antiproliferation in response to IFNb c-Cbl has been previously implicated in the regulation of the cellular response to growth factors such as EGF, presumably by targeting internalized receptors for ubiquitin-dependent degradation (Levkowitz et al., 1998; . We were interested in determining whether c-Cbl would play a similar role in regulating signal transduction through cytokine receptors such as the IFNa/b receptor. We therefore isolated murine embryonic ®broblasts from either wild-type or c-Cbl7/7 mice to test their responsiveness towards the antiproliferative eects of murine IFNb. In addition, two reconstituted clones, R1 and R2, were independently isolated after retroviral introduction of c-Cbl into the c-Cbl de®cient MEFs. Expression of c-Cbl in these four cell lines was determined by Western blotting of resolved whole cell lysate with a monoclonal anti-cCbl antibody. As shown in Figure 1a , the wild-type MEFs, and the two reconstituted clones express comparable levels of c-Cbl (lanes 1, 3 and 4), whereas the MEFs established from the c-Cbl7/7 mice lack detectable c-Cbl protein (lane 2). The faint band with slightly faster mobility has been observed before, and represents a non-functional protein originating from the mutant allele (Murphy et al., 1998) .
In order to determine whether c-Cbl7/7 cells displayed an altered sensitivity towards the antiproliferative eects of IFNb, we stimulated these cells with 100 U/ml IFNb, and analysed cell growth over a 5 day period. Indeed, c-Cbl7/7 cells were signi®cantly more inhibited in their proliferation by IFNb than wild-type MEFs or the reconstituted clones R1 and R2 (Figure 1b) . It is important to note that all cell lines displayed similar growth rates in the absence of IFNb (data not shown). To further explore the observed increase in antiproliferative eects of IFNb in the absence of c-Cbl, we performed a dose-response analysis by determining inhibition of cell growth at 10, 100 or 1000 U/ml IFNb over a 3 day period. As expected, all concentrations of IFNb triggered a stronger antiproliferative response in c-Cbl7/7 cells than in the wild-type MEFs or in the reconstituted clones R1 and R2 (Figure 1c ). Similar results were obtained when murine IFNa was used for stimulation (data not shown). These results demonstrate that cCbl not only plays an essential role in the cellular response to growth factors, but also modulates the biological response to antiproliferative cytokines such as IFNb. Since the antiproliferative eect of IFNb requires the activation of the Jak ± STAT signal transduction pathway, we compared the levels of STAT1 tyrosine phosphorylation in wild-type, c-Cbl7/7, and the two reconstituted cell lines after IFNb stimulation. As shown in Figure 2a , the absence of c-Cbl results in dramatically increased phosphorylation of STAT1 in response to IFNb (compare upper panel, lane 4 with lanes 2, 6, and 8), however, the half-life of tyrosine phosphorylated STAT1 appeared to be similar in all cells (data not shown). Surprisingly, when the blot was reprobed for STAT1, we found that the c-Cbl7/7 cells contained signi®cantly higher levels of STAT1 protein (lower panel, lanes 3, 4) when compared to cells expressing c-Cbl (lower panel, lanes 1, 2; 5, 6; 7, 8).
Next, we analysed the protein levels of other STAT family members to test whether the eect of c-Cbl7/7 was speci®c for STAT1, or would globally alter the expression of STATs. Immunoblot analysis of lysates derived from wild-type, c-Cbl7/7, R1 and R2 cells for the presence of STAT1, 2, 3 and 5 revealed that the absence of c-Cbl7/7 causes an increase in the amounts of STAT1 and STAT5 protein, whereas the levels of STAT2 and STAT3 protein remained unaected ( Figure 2b ).
The protein expression levels of the two Janus tyrosine kinases involved in IFNab signaling, Jak1 and Tyk2, also appear to be regulated independently of c-Cbl (Figure 2c ). Interestingly, c-Cbl7/7 MEFs displayed a higher level of basal tyrosine phosphorylation of Tyk2 and Jak1 when compared to the reconstituted cell lines. However, no dierence in the extent of Jak1 and Tyk2 tyrosine phosphorylation was observed between the c-Cbl7/7 and reconstituted cells after stimulation of with IFNb for 15 min. It is also noteworthy that the increased basal tyrosine phosphorylation of Jak1 and Tyk2 in c-Cbl7/7 cells does not translate into a constitutive tyrosine phosphorylation of STAT1 (Figure 2a ,c) or STAT2 (data not shown). Interestingly, Erk1/2 phosphorylation, although constitutive, was found to be similar in all cell lines tested (data not shown), indicating that the loss of c-Cbl does not result in a general dysregulation of signaling pathways.
STAT1 mRNA levels are unchanged in c-Cbl-deficient MEF cells
The observed increase in STAT1 protein observed in cCbl7/7 cells could be due to changes in transcription or mRNA stability, or could be regulated on a posttranscriptional level. To address this question, we performed RNAse protection assays using a radiolabeled STAT1 antisense RNA probe in order to determine the levels of STAT1 mRNA in the wild-type, c-Cbl7/7, and the two reconstituted cell lines. A GAPDH antisense probe was used as an internal control for RNA isolation and processing. No signi®cant dierence in the amount of STAT1 mRNA between the cell lines could be detected (Figure 3 upper panel, compare lane 2 with lanes 1, 3 and 4). This was further con®rmed by densitometric analysis and normalization to GAPDH (Figure 3, lower panel) . Thus, the increased amount of STAT1 protein in the . C-Cbl7/7, R1, and R2 cells were stimulated with 1000 U/ml IFNb for the indicated times, and cell lysates were immunoblotted with phospho-Tyk2 speci®c antibody (upper panel). The remaining lysate was subject to immunoprecipitation with Jak1 antisera, and isolated proteins were immunoblotted with 4G10 phosphotyrosine antibody (upper panel). Both blots were reprobed for total Tyk2 and Jak1 protein, respectively (lower panels) absence of c-Cbl appears to originate at a posttranscriptional level, either by increased STAT1 protein synthesis, or by decreased STAT1 protein turnover.
c-Cbl Regulates STAT1 synthesis, but not degradation c-Cbl has been shown to participate in the downregulation of other signaling events, notably the EGF receptor pathway, by promoting the ubiquitination and proteasome-dependent degradation of components of the signaling cascade. Since it had been previously suggested that phosphorylated STAT1 protein might be subject to proteasome-mediated degradation (Kim and Maniatis, 1996) , we reasoned that c-Cbl functions by facilitating ecient degradation of STAT1 protein, even in the absence of its phosphorylation. To test whether c-Cbl represses STAT1 protein levels by ubiquitin-mediated proteolysis, c-Cbl7/7, R1 and R2 cells were treated for either 1 or 6 h with 40 mM MG132, a potent proteasome inhibitor. The resulting cell lysates were then analysed for STAT1 expression levels. Unexpectedly, inhibition of proteasomemediated protein degradation by MG132 was ineective in elevating STAT1 levels in the c-Cbl-expressing R1 and R2 cells (Figure 4a, lanes 4 ± 9) . Furthermore, MG132 treatment was also unable to cause an additional increase in STAT1 levels in the c-Cbl7/7 cells (lanes 1 ± 3) . TNFa-mediated IkB degradation in untreated or MG132 pretreated cells was used to con®rm the inhibitory eects of MG132 on proteasome-mediated degradation in these MEFs (Figure 4b ). These results suggested that c-Cbl exerts its negative regulatory eects on STAT1 expression by suppressing the translation of STAT1 rather than promoting proteasome-mediated degradation.
To investigate this hypothesis, we performed metabolic pulse-labeling experiments on c-Cbl7/7 and the reconstituted MEFs. Since these cell lines express dierent levels of STAT1 protein, we decided to use a limiting amount of STAT1 antibody in order to immunoprecipitate equal amounts of STAT1 protein from each of the cell lines. Immunoprecipitates of STAT1 and STAT3 derived from 35 S-Met/Cys-labeled cells were resolved by SDS ± PAGE, transferred to membranes, and the radiolabeled proteins detected by autoradiography. Strikingly, we found that STAT1 protein synthesis occurs at a dramatically faster rate in c-Cbl7/7 cells than in their reconstituted counterparts (Figure 5a , lane 1 versus 2 and 3). In striking contrast, the rate of STAT3 protein synthesis was unaected by the absence of c-Cbl (lanes 4 ± 6). As such, the identical incorporation of label into STAT3 does not only function as an internal control to verify ecient labeling of the reconstituted cells, but also reinforces our observations depicted in Figure 2b . To further ensure that equal amounts of immunoprecipitated protein from all three cell lines were loaded, the membranes were subsequently immunoblotted for total STAT1 and STAT3 protein (Figure 5a, lower panel) .
To further evaluate whether the half-life of STAT1 was indeed unaected by the presence of c-Cbl as suggested by the inability of MG132 to increase STAT1 levels in c-Cbl-containing cells, we performed 35 S-pulse-chase experiments. C-Cbl7/7 and R1 cells were labeled with 35 S-Met/Cys for 4 h as described above, the 35 S-Met/Cys-containing media replaced with regular culture medium, and the cells were incubated and R2 (lane 4) cells was analysed by RNase protection assay using a probe corresponding to the human STAT1 gene. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control for loading. The bar graph depicts the quantitated results, normalized for GAPDH Figure 4 Proteasome inhibitor MG132 does not aect STAT1 protein levels: (a) c-Cbl7/7 and reconstituted MEFs R1 and R2 were left untreated (lanes 1, 4 and 7) or treated for the indicated times with 40 mM MG132 (lanes 2 ± 3, 5 ± 6 and 8 ± 9). Proteins were immunoblotted with anti-STAT1 antibody. (b) R1 cell were treated with TNFa for 30 min in the presence or absence of 40 mM MG132, and lysates were probed for the presence of IkB for an additional 1, 2, 4, 8 or 24 h. Although the cCbl7/7 cells showed again a signi®cantly increased rate of protein synthesis, neither one of the cell lines tested displayed an appreciable reduction in the amount of 35 S-labeled STAT1 protein over the time periods analysed (data not shown). These results further illustrate that c-Cbl aects protein levels of STAT1 by a mechanism distinct from promoting proteasomal degradation.
The above experiment indicated that the half-life of STAT1 was unaected by the presence of c-Cbl, and that dierences in the translation of the endogenous STAT1 mRNA account for the increased STAT1 levels in c-Cbl7/7 cells. To further con®rm this hypothesis, the half-life of HA-tagged STAT1, expressed under the control of a CMV promoter, was determined in cCbl7/7 and R1 cells. In this scenario, equal amounts of radiolabeled STAT1 protein are produced in wildtype and c-Cbl7/7 cells (Figure 5b, lanes 1 and 6) . As expected, the stability of HA-STAT1 synthesized from the plasmid in c-Cbl7/7 cells is essentially identical to that observed in the presence of c-Cbl. Although it is evident that HA-STAT1 is subject to degradation over time, the underlying mechanism appears to be independent of c-Cbl.
Lastly, if the half life of STAT1 would be aected by the ubiquitin ligase activity of c-Cbl, then coexpression c-Cbl, but not the ubiquitin-ligase activity de®cient 70Z-Cbl, should reduce the protein levels of HA-tagged STAT1. However, when coexpressed in c-Cbl7/7 cells, neither c-Cbl nor 70Z-Cbl eect the expression levels of HA-tagged STAT1 (Figure 5c, lanes 2 and 3) . These results further support the notion that c-Cbl does not in¯uence the half-life of STAT1 protein.
Discussion
In recent years, c-Cbl has been extensively studied as a negative regulator of activated growth factor or antigen receptors. Common to the mechanism in each case is the recruitment of c-Cbl to the tyrosine phosphorylated receptors, and the subsequent ubiquitin-mediated degradation of either the receptor itself (Lee et al., 1999; Levkowitz et al., 1998; , or of associated tyrosine kinases and their substrates (Ota and Samelson, 1997; Thien et al., 1999) . In contrast, the role of c-Cbl in cytokine signaling remained to be explored in much greater detail. In the present study, we utilized murine embryonic ®broblasts derived from c-Cbl-de®cient mice, and two independently reconstituted cell lines to investigate the role of c-Cbl in the biological eects of IFNb. We demonstrate that the loss of c-Cbl results in an increased antiproliferative response of the cells towards IFNb. This hyperresponsiveness is caused by increased levels of STAT1 tyrosine phosphorylation, which in turn is due to elevated expression of STAT1 protein.
Remarkably, STAT2 and STAT3 protein levels were apparently not aected by the presence or absence of c-Cbl. The increase in STAT1 protein amounts in c-Cbl7/7 cells is regulated on a post-transcriptional level, since identical levels of STAT1 mRNA were detected in all cell lines tested.
Thus far, c-Cbl has been investigated predominantly as a component of the protein degradation pathway, where it acts as an E3 ubiquitin ligase in the multiubiquitination process of proteins targeted for degradation (Joazeiro et al., 1999) . Although ubiquitination has been suggested as a mechanism to downregulate activated, tyrosine phosphorylated STAT1 protein after IFNg treatment (Kim and Maniatis, 1996) , we were unable to detect such a modi®cation in unstimulated MEFs. Incubation of the c-Cbl-containing MEFs with the proteasome inhibitor MG132 was also unable to elevate STAT1 levels in those cells. Furthermore, pulse-chase experiments with the protein synthesis inhibitor cycloheximide revealed that STAT1 protein is very stable, displaying a half-life of greater than 24 h (data not shown). Lastly, it is also noteworthy that the observed dierences in STAT1 protein levels caused by the absence of c-Cbl occur in a ligand-independent manner, and therefore have to be regulated independently of STAT1 phosphorylation.
c-Cbl has previously been reported to be an inhibitor of EGF-induced STAT activation (Ueno et al., 1997) . In these experiments, antisense repression of c-Cbl resulted in an increased phosphorylation of Jak1 and STAT3 in response to EGF, whereas phosphorylation of SOS and Shc was unaected by the loss of c-Cbl. As c-Cbl clearly regulates degradation of the activated EGF receptor, it is obvious that dierent requirements exist for EGF to activate distinct signaling cascades. Indeed, a kinase-inactive EGF receptor is still able to mediate Shc phosphorylation and MAP-kinase activation, presumably by dimerizing with other ErbB family members, but fails to induce the tyrosine phosphorylation of Jak1 and STAT proteins (David et al., 1996; Wright et al., 1995) .
Taken together, these results led us to analyse STAT1 protein translation by metabolic labeling of cCbl-containing and c-Cbl-de®cient cells. Indeed, drastically enhanced translation eciency of STAT1 was detectable in the absence of c-Cbl. Importantly, this eect was speci®c for STAT1, as radiolabel incorporation into STAT3 was unaected by c-Cbl. These results con®rm our ®ndings of increased STAT1, but not STAT3, protein levels in c-Cbl7/7 cells. It thus appears that c-Cbl is able to exert its negative regulatory function by means other than promoting ubiquitination of phosphoproteins.
Intriguingly, when STAT1 was expressed from a CMV-promoter controlled expression plasmid, no dierence between c-Cbl7/7 and the reconstituted cells was observed with regard to STAT1 protein levels, or STAT1 metabolic labeling. This further supports the hypothesis that c-Cbl regulates STAT1 levels independently of proteolytic degradation. Since the exogenous STAT1-cDNA encodes only the open-reading frame of STAT1, it is likely that the eects of c-Cbl on STAT1 protein translation from endogenous mRNA are directly or indirectly mediated by sequences in the 3' and 5' UTRs. Indeed, the importance of mRNA untranslated regions in translation eciency has previously been demonstrated (Cok and Morrison, 2001; Gray, 1998; Lokvist et al., 2001) . However, further research is required to determine whether c-Cbl mediates the tranalational control directly, or if other factors involved in translational regulation are in¯u-enced by the functions of c-Cbl.
Although we had expected that c-Cbl might function as a negative regulator of the Jak/STAT pathway, it was surprising to ®nd inhibition of STAT1 protein synthesis as the underlying mechanism. The lack of an MG132 eect, increased STAT1 metabolic labeling in the absence of c-Cbl, and the absence of appreciable dierences in STAT1 half-life provide strong evidence for a novel, protein degradation-independent basis by which c-Cbl can negatively regulate expression of certain proteins.
Materials and methods

Cells and reagents
Murine embryonic ®broblasts (MEFs) were derived from d13 embryos of wild-type and c-Cbl7/7 mice by trypsinization and homogenization. Two independently reconstituted cells lines, R1 and R2, were obtained by retroviral introduction of c-Cbl into c-Cbl7/7 MEFs, and subsequent selection of puromycin-resistant clones. MEFs were cultured in DMEM supplemented with 10% FCS, penicillin, and streptomycin (Irvine Scienti®c). Murine IFNb was expressed in CHO cells and puri®ed to homogeneity either as described (Luca et al., 1999) . The potency of the puri®ed murine IFNb was determined in an antiviral assay using L929 cells and the encephalomyocarditis virus. In such assays, the protein had a speci®c activity of *2610E8 Units/mg, where one unit of activity is de®ned as the concentration of murine IFNb that gives 50% protection. MG 132 was purchased from Calbiochem (La Jolla, CA, USA).
Western blot analysis
Following treatment, cells were washed with PBS and lysed with lysis buer (150 ml) containing 20 mM HEPES pH 7.4, 1% Triton X-100, 100 mM NaCl, 50 mM NaF, 10 mM bglycerophosphate, 1 mM sodium vanadate, and 1 mM PMSF. Lysates were centrifuged at 15 000g for 15 min at 48C and protein concentration was determined by Bradford (BioRad). Equivalent concentrations of protein were boiled in SDS sample buer containing b-mercaptoethanol, resolved by SDS ± PAGE (BioRad), and electrotransferred onto Immobilon-P membranes (Millipore). After transfer, proteins were detected with speci®c antibodies against c-Cbl, STAT1, STAT2, STAT3, STAT5, Tyk2, Jak1, ERK2 (Transduction Laboratories), phospho-STAT1, phospho-Tyk2 (New England Biolabs), HA (BabCo) and IkB (Santa Cruz Biotech). All blots were developed with horseradish peroxidaseconjugated secondary antibodies and enhanced chemiluminescence (Amersham).
RNAse protection assay
Total RNA was isolated with TRIzol (Gibco BRL), and 32 Plabeled antisense riboprobes were generated by in vitro transcription using T7 or SP6 RNA polymerase (Promega). The *500 base STAT1 antisense probe was generated via T7 promoter-mediated transcription of SmaI-linearized BSKS ± STAT1. Labeled probes were incubated with 10 mg total RNA overnight at 568C before digestion with T1 RNAse (Gibco BRL) for 1 h at 378C. After phenol extraction, protected fragments were boiled in RNA sample buer and resolved by electrophoresis on a 4.5% polyacrylamide-urea gel.
Cell proliferation assay
MEFs were plated in 96-well plates and left untreated or treated with 10, 100, 1000 U/ml murine IFNb. On the indicated days, one plate was subject to a colorimetric MTS assay (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay, Promega) according to the manufacturers instructions. Unless otherwise indicated, eight samples were averaged, and for each cell line IFNb-induced antiproliferation was determined as the percentage of growth inhibition relative to untreated cells.
Metabolic labeling and immunoprecipitations
Cell labeling was performed with 80% con¯uent MEFs in 60-mm tissue culture dishes. Cells were rinsed once with methionine and cysteine-free media, then pulsed for 4 h with 800 mCi/ml 35 S-methionine and 35 S-cysteine (Tran 35 S-Label) in the same media. For chase-type experiments, the labeling media was replaced with DMEM + 10% FBS, and the cells further incubated for the indicated times. Cells were lysed as described above, and labeled proteins were immunoprecipitated from pre-cleared cell lysates with previously described antisera (5 ml/mg protein) against STAT1 and STAT3 (David et al., 1996) . For experiments shown in Figure 5a , 0.5 ml STAT1 antiserum per mg protein was used. Immunoprecipitates of Protein G Sepharose beads (Pharmacia Biotech) were resolved by SDS ± PAGE and electrotransferred to Immobilon-P membranes (Millipore). Membranes were then exposed to Biomax-MR ®lm (Kodak) for 24 ± 48 h at 7708C prior to reprobing with anti-STAT1 and anti-STAT3 antibodies.
cDNAs and transient transfections
MEFs were transfected using SuperFect (Qiagen) according to the manufacturer's protocol for 48 h with pSG91-HA-STAT1 prior to metabolic labeling.
